Hepatocellular Carcinoma (HCC)
Conditions
Keywords
hepatocellular carcinoma, 68Ga-FAPI, PET/CT
Brief summary
This study aims to investigate the value of 68Ga-FAPI PET/CT in the efficacy evaluation of advanced unresectable hepatocellular carcinoma patients undergoing systemic antitumor therapy.
Detailed description
The investigators will number all participants, create a medical record file, and record their basic information (gender, age) as well as contact information and medical history information. All participants will undergo a 68Ga-FAPI PET/CT before treatment and after 3-month treatment. The imaging response measurements will be compared with the histopathological results as gold standard.
Interventions
None listed
Sponsors
Ruijin Hospital
Study design
Observational model
OTHER
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. Pathological and clinical diagnosis of advanced unresectable hepatocellular carcinoma patients. 2. Signed and dated informed consent form. 3. Commitment to comply with research procedures and co-operation in the implementation of the full research process. 4. Aged 18-75 years old.
Exclusion criteria
1. Patients with serious illnesses that researchers consider unsuitable for participation in this clinical study. Such as severe heart and lung failure, severe bone marrow suppression, severe liver and kidney dysfunction, etc. 2. Intestinal perforation, complete intestinal obstruction 3. Pregnant women and women who may be pregnant, women who are breastfeeding. 4. Non-compliant person
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The responses to systemic antitumor therapy of advanced unresectable hepatocellular carcinoma | Within 1 week of enrollment and up to 3 months | The tumor lesions were evaluated within one week of enrollment and at 3 months of treatment, and a comparison was made before and after. Those with improved tumor lesions were considered to have responded to the treatment, while those without improved tumor lesions were considered to have no response to the treatment. |
| Standardized uptake value(SUV) | Within 1 week of enrollment and after up to 3 months | SUV of 68Ga-FAPI uptake on PET/CT images for tumor lesions |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Progress free survival | 3 years | Progress free survival |
| Overall survival | 3 years | Overall survival |
Countries
China
Contacts
Primary ContactJiajia Hu
Outcome results
None listed